EGFR mutant tumor cells also showed upregulation of ‘interferon gamma response’ and ‘allograft rejection’, whereas KRAS-mutated tumor cells showed upregulation of the ‘TNFa signaling via NFκB pathway’, consistent with previous studies36 (Supplementary Fig. 2.4b). The gene discussed is EGFR; the disease is neoplasm.